Bernhard Peball

I design aseptic manufacturing processes for cell therapies that are built for the clinic from the start. With 35 years of experience across cell isolation, fermentation, electroporation, and clinical tech transfer, I work best at the stage where something scientifically promising needs to become something operationally reliable and inspection-ready.

As a consultant, I have contributed to building several organisations from concept to commercial success.

• Since 2018 Focus on adoptive cell therapy: co-inventor of autologous manufacturing processes, non-viral transfection, tech transfers for decentralised trials, CMC team participation.
• 2022 – invIOs GmbH, resulting from Apeiron Biologics demerger — two clinical trials with transfected autologous PBMCs in solid tumours, preclinical TIL program in glioblastoma.
  Includes lead invention of CellMo, a large-volume electroporation device and consumables for patient cells designed for integration into closed aseptic workflows, patent filed 2025 (pending), currently entering clinical use: www.cellmo.at
• 2005 – 2022 From founding to demerger: Apeiron Biologics AG — antibody and recombinant enzyme fermentation in roller systems and hollow fibre bioreactors; preclinical-scale manufacturing; co-inventorship on multiple therapy patents. Several projects transitioned to clinic, one achieved marketing authorisation, which ultimately led to a company transaction.
• 2016 – 2018 Company startup: RMB Research GmbH — preclinical biotech specialised in wound healing.
• 1999 – 2004 From founding to merger: Igeneon AG — developed methods for detection of epithelial tumour cells in peripheral blood as, an early form of liquid biopsy at a time when the field was nascent — methods subsequently used in Phase I clinical trials to demonstrate efficacy.
• 1989 – Began in the field as a technician; built laboratory and manufacturing expertise at HZL, OMV, Sandoz/Novartis over a decade while completing a Bachelor in Biotechnology.

If you are building cell therapy manufacturing capabilities and need someone who has done it before — let's talk.